Fenwick & West represented Dermira, Inc., a specialty biopharmaceutical company focused on bringing innovative and differentiated medical dermatology products to dermatologists and their patients, in its $51 million Series C financing. Existing investors Bay City Capital, New Enterprise Associates (NEA), Canaan Partners and UCB S.A. were joined by new investors Apple Tree Partners, Aisling Capital, Rock Springs Capital, Sabby Capital and other healthcare investors, in the transaction.
The Fenwick transaction team was led by corporate partners Doug Cogen and Michael Brown and corporate associates Morgan Casey and Liza Kostinskaya.